RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+16%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$434M
AUM Growth
+$434M
(+55%)
Cap. Flow
+$135M
Cap. Flow
% of AUM
31.23%
Top 10 Holdings %
Top 10 Hldgs %
39.11%
Holding
88
New
19
Increased
48
Reduced
6
Closed
13
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$24.6M |
| 2 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$10.1M |
| 3 |
ITMN
INTERMUNE INC
ITMN
|
$9.54M |
| 4 |
AbbVie
ABBV
|
$6.94M |
| 5 |
UnitedHealth
UNH
|
$6.64M |
Top Sells
| 1 |
Health Care Select Sector SPDR Fund
XLV
|
$9.94M |
| 2 |
GENT
GENTIUM SPA ADS
GENT
|
$6.82M |
| 3 |
AET
Aetna Inc
AET
|
$4.27M |
| 4 |
Puma Biotechnology
PBYI
|
$2.89M |
| 5 |
Edwards Lifesciences
EW
|
$2.8M |
Sector Composition
| 1 | Healthcare | 79.37% |
| 2 | Industrials | 1.53% |
| 3 | Technology | 0.49% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Johnson & Johnson
JNJ
$427B
| $24.6M | 5.66% | +250,000 | New | +$24.6M |
|
2
Gilead Sciences
GILD
$140B
| $23.5M | 5.41% | 331,000 +46,000 | +16% | +$3.26M |
|
|
3
AbbVie
ABBV
$372B
| $18.5M | 4.27% | 360,000 +135,000 | +60% | +$6.94M |
|
4
Biogen
BIIB
$19.4B
| $16.9M | 3.9% | 55,250 +2,250 | +4% | +$688K |
|
5
McKesson
MCK
$85.4B
| $16.2M | 3.73% | 91,500 +28,500 | +45% | +$5.03M |
|
|
6
UnitedHealth
UNH
$281B
| $14.8M | 3.42% | 181,000 +81,000 | +81% | +$6.64M |
|
|
THOR
7
DELISTED
THORATEC CORPORATION
THOR
| $14.4M | 3.31% | 401,000 +126,000 | +46% | +$4.51M |
|
8
Amgen
AMGN
$155B
| $14.2M | 3.27% | 115,000 +36,000 | +46% | +$4.44M |
|
|
ITMN
9
DELISTED
INTERMUNE INC
ITMN
| $13.7M | 3.17% | 410,000 +285,000 | +228% | +$9.54M |
|
10
Thermo Fisher Scientific
TMO
$186B
| $12.9M | 2.97% | 107,250 +39,750 | +59% | +$4.78M |
|
|
11
Health Care Select Sector SPDR Fund
XLV
$33.9B
| $11.7M | 2.7% | 200,000 -170,000 | -46% | -$9.94M |
|
|
AGN
12
DELISTED
Allergan plc
AGN
| $11.6M | 2.67% | 56,250 +31,750 | +130% | +$6.54M |
|
|
CELG
13
DELISTED
Celgene Corp
CELG
| $10.7M | 2.48% | 77,000 +15,000 | +24% | +$2.09M |
|
|
AVDL
14
Avadel Pharmaceuticals
AVDL
$1.43B
| $10.1M | 2.32% | +750,000 | New | +$10.1M |
|
15
Bristol-Myers Squibb
BMY
$96B
| $9.64M | 2.22% | 185,500 +5,000 | +3% | +$260K |
|
16
Agilent Technologies
A
$35.7B
| $8.67M | 2% | 155,000 +22,000 | +17% | +$1.23M |
|
17
CVS Health
CVS
$92.8B
| $8.46M | 1.95% | 113,000 +58,250 | +106% | +$4.36M |
|
18
Cooper Companies
COO
$13.4B
| $8.31M | 1.92% | 60,500 +44,000 | +267% | +$6.04M |
|
19
Intuitive Surgical
ISRG
$170B
| $8.1M | 1.87% | 18,500 +1,000 | +6% | +$438K |
|
20
Humana
HUM
$36.5B
| $7.38M | 1.7% | 65,500 +32,500 | +98% | +$3.66M |
|
|
ALXN
21
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $7.38M | 1.7% | 48,500 -2,500 | -5% | -$380K |
|
22
Bausch Health
BHC
$2.74B
| $6.99M | 1.61% | 53,000 +6,000 | +13% | +$791K |
|
23
Illumina
ILMN
$15.8B
| $6.32M | 1.46% | 42,500 -12,750 | -23% | -$1.9M |
|
|
TMH
24
DELISTED
Team Health Holdings Inc
TMH
| $5.43M | 1.25% | 121,250 +3,750 | +3% | +$168K |
|
|
OREX
25
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $5.4M | 1.24% | 830,000 +305,000 | +58% | +$1.98M |
|